Biblio

Author [ Title(Desc)] Type Year
Filters: Author is Zinzani, Pier Luigi  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Chiappella A, Casadei B, Chiusolo P, Di Rocco A, Ljevar S, Magni M, Angelillo P, Barbui AMaria, Cutini I, Dodero A, et al. Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study. Leukemia. 2024.
B
Stefoni V, Argnani L, Carella M, Casadei B, Morigi A, Lolli G, Broccoli A, Pellegrini C, Nanni L, Coppola PElia, et al. BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience. J Cancer Res Clin Oncol. 2022.
Driessen J, de Wit F, Herrera AF, Zinzani PLuigi, Lacasce AS, Cole PD, Moskowitz CH, Garcia-Sanz R, Fuchs M, Mueller H, et al. Brentuximab Vedotin and Chemotherapy in Relapsed/Refractory Hodgkin Lymphoma: a Propensity Score Matched Analysis. Blood Adv. 2024.
C
Ravandi F, Kreitman RJ, Tiacci E, Andritsos L, Banerji V, Barrientos JC, Bhat SA, Blachly JS, Broccoli A, Call T, et al. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood Cancer J. 2022;12(12):165.
D
Giladi O, Bagnato G, Gentilini M, Shimony S, Pasvolsky O, Berger T, Itchaki G, Raanani P, Lolli G, Stefoni V, et al. Diffuse large B cell lymphoma characteristics and outcomes during the COVID-19 pandemic in two tertiary centers - an Israeli/ Italian study. Ann Hematol. 2023.
Dreyling M, Fowler NH, Dickinson M, Martínez-López J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, et al. Durable Response After Tisagenlecleucel in Adults With Relapsed/Refractory Follicular Lymphoma: ELARA Trial Update. Blood. 2024.
E
Gentilini M, Casadei B, Broccoli A, Argnani L, Cavo M, Zinzani PLuigi. Elderly Non-GCB Diffuse Large B-Cell Lymphoma Patient Responding to Lenalidomide after Epicardial Relapse: A Case Report. Acta Haematol. 2020:1-4.
H
Lolli G, Casadei B, Stefoni V, Argnani L, Bonifazi F, Zinzani PLuigi. Hepatosplenic T-cell non-Hodgkin lymphoma cured with tandem autologous and allogeneic stem cell transplantation. Chemotherapy. 2022.
I
Broccoli A, Argnani L, Zinzani PLuigi. Invited Review: Will Consolidation with ASCT Be a Thing of the Past for MCL and PTCL?. Curr Hematol Malig Rep. 2021.
M
Zaja F, Federico M, Vitolo U, Zinzani PLuigi. Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies. Leuk Lymphoma. 2013.
N
Vegliante MCarmela, Mazzara S, Zaccaria GMaria, De Summa S, Esposito F, Melle F, Motta G, Sapienza MRosaria, Opinto G, Volpe G, et al. NR1H3 (LXRα) IS ASSOCIATED WITH PRO-INFLAMMATORY MACROPHAGES, PREDICTS SURVIVAL AND SUGGESTS POTENTIAL THERAPEUTIC RATIONALES IN DIFFUSE LARGE B-CELL LYMPHOMA. Hematol Oncol. 2022.
P
von Tresckow B, Fanale M, Ardeshna KM, Chen R, Meissner J, Morschhauser F, Moskowitz C, Zinzani PLuigi, Giezek H, Balakumaran A, et al. Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma. Leuk Lymphoma. 2019:1-7.
Zinzani PLuigi, Chen R, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, et al. Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis. Leuk Lymphoma. 2020:1-5.
Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, Fogliatto LMaria, Goncalves I, de Oliveira JSR, Buccheri V, et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2021.
Broccoli A, Zinzani PLuigi. Peripheral T-cell lymphomas. Hematol Oncol. 2023;41 Suppl 1:82-87.
Casadei B, Argnani L, Morigi A, Lolli G, Broccoli A, Pellegrini C, Nanni L, Stefoni V, Coppola PElia, Carella M, et al. Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: a real-life experience. Hematol Oncol. 2020.
Q
Zinzani PLuigi, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, Oliveira JSR, Buccheri V, Perini GFleury, Dickinson M, et al. Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma. Blood Adv. 2021.
R
Nowakowski GS, Yoon DHyun, Mondello P, Joffe E, Peters A, Fleury I, Greil R, Ku M, Marks R, Kim K, et al. RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large . Ann Hematol. 2023.
S
Bagnato G, Stefoni V, Broccoli A, Argnani L, Pellegrini C, Casadei B, Bonifazi F, Zinzani PLuigi. Successful Bridging to Allogeneic Transplantation With Valemetostat in Two Refractory/relapsed Peripheral T-cell lymphoma patients. Mediterr J Hematol Infect Dis. 2024;16(1):e2024004.
T
Broccoli A, Argnani L, Gugliotta G, Pellegrini C, Casadei B, Bagnato G, Gentilini M, Stefoni V, Zinzani PLuigi. The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation. Oncologist. 2024.